|
AECA and ANCA directed to specific antigens other than MPO
|
Number and percentage with ANCA specificity
|
|---|
|
Patients with PTU-induced vasculitis
|
Patients with PTU-induced MPO-ANCA but without clinical vasculitis
|
P value
|
|---|
|
(n = 17)
|
(n = 11)
|
|---|
|
AECA
|
15 (88.2%)
|
0 (0)
|
<0.001
|
|
PR3
|
5 (29.4%)
|
1 (9.1%)
|
0.380
|
|
HLE
|
12 (70.6%)
|
3 (27.3%)
|
0.011
|
|
Lactoferrin
|
14 (82.4%)
|
5 (45.5%)
|
0.010
|
|
Cathepsin G
|
11 (64.7%)
|
0 (0)
|
<0.001
|
|
BPI
|
0 (0)
|
1 (9.1%)
|
0.209
|
|
Azurocidin
|
12 (70.6%)
|
1 (9.1%)
|
<0.001
|
|
Number of ANCA target antigens recognized
|
3 (2–4)
|
0 (0–2%)
|
<0.001
|
- PR3, Proteinase 3; HLE, human leukocyte elastase; BPI, bactericidal/permeability-increasing protein.
